Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep 15;61(9):1143-51.
doi: 10.1002/art.24698.

Novel evidence-based systemic lupus erythematosus responder index

Richard A Furie  1 , Michelle A Petri, Daniel J Wallace, Ellen M Ginzler, Joan T Merrill, William Stohl, W Winn Chatham, Vibeke Strand, Arthur Weinstein, Marc R Chevrier, Z John Zhong, William W Freimuth
Affiliations

Novel evidence-based systemic lupus erythematosus responder index

Richard A Furie et al. Arthritis Rheum. .

Abstract

Objective: To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials.

Methods: Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies >/=1:80 and/or anti-double-stranded DNA antibodies >/=30 IU/ml) at baseline was retrospectively evaluated using the SRI.

Results: SRI response is defined as 1) a >/=4-point reduction in SELENA-SLEDAI score, 2) no new BILAG A or no more than 1 new BILAG B domain score, and 3) no deterioration from baseline in the physician's global assessment by >/=0.3 points. In serologically active patients, the addition of belimumab to SOC resulted in a response in 46% of patients at week 52 compared with 29% of the placebo patients (P = 0.006). SRI responses were independent of baseline autoantibody subtype.

Conclusion: This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.

Trial registration: ClinicalTrials.gov NCT00071487.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Belimumab effect on SELENA-SLEDAI score at week 52 in serologically active patients (N=321)
(A) Percent change in SELENA-SLEDAI from baseline over time. (B) Absolute changes from baseline in SELENA-SLEDAI score at week 52. (C) Percentage of patients with ≥4-point reduction in SELENA-SLEDAI score. a Statistically significant better response with belimumab all active vs placebo (P=0.04). b Statistically significant better response with belimumab all active vs placebo (P<0.05).
Figure 2
Figure 2. Belimumab effect on PGA and SF-36 scores at week 52 in serologically active patients (N=321)
(A) Percent change in PGA. (B) Absolute point change in SF-36 PCS. a Statistically significant better response with belimumab all active vs placebo (P<0.05).
Figure 3
Figure 3. Belimumab effect on BILAG domain scores at week 52 (new A or B scores)
Percent of serologically active patients with new 1A or 1B BILAG organ domain scores at week 52. a Statistically significant better response with belimumab all active vs placebo (P<0.05).
Figure 4
Figure 4. (A) SLE Responder Index over 52 weeks in serologically active patients (N=321). (B) Response rate at week 52 in belimumab-treated patients with different autoantibody subtypes at baseline
a Statistically significant better response with belimumab all active vs placebo (P=0.006).
See this image and copyright information in PMC

Comment in

References

    1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929–39. - PubMed
    1. ACR Ad Hoc Committee. Guidelines for Referral and Management of Systemic Lupus Erythematosus in Adults. Arthritis Rheum. 1999;42(9):1785–96. - PubMed
    1. Strand V. Lessons learned from clinical trials in SLE. Autoimmun Rev. 2007;6(4):209–14. - PubMed
    1. FDA. Guidance for Industry Systemic Lupus Erythematosus - Developing Drugs for Treatment. 2005. [Last accessed on 8/12/2008]. http://www.fda.gov/cder/guidance/6496dft.pdf.
    1. Bertsias G, Gordon C, Boumpas D. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus. 2008;17(5):437–42. - PubMed

Publication types

MeSH terms

Associated data